Supplementary Figures 1 - 9 from BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

<p>PDF file - 427KB, Figure S1 Identification of BRAFV600E splice variants in Prog tumor derived from Patient 9. Figure S2 Representative Sanger sequencing traces. Figure S3 Level of V600E BRAF allele relative to the wild type BRAF allele. Figure S4 Linear models of MEK1 and MEK2 showing functional domains. Figure S5 ATMR337C does not confer resistance to dabrafenib. Figure S6 Transcript expression analyses of additional BRAF inhibitor resistance mechanisms. Figure S7 Expression of PDGFRbeta in melanoma biopsy samples from patient 3. Figure S8 Differential expression of pAKT in two Prog tumors derived from patient 10 (Prog 1 MAPK-inhibited and Prog 2 MAPK re-activated). Figure S9 Melanoma cells expressing BRAF splice variants are resistant to dabrafenib, but retain sensitivity to trametinib.</p>